



Dear SMA UK,

Thank you for your request for information regarding the availability of nusinersen high dose regimen (50/28 mg) for the treatment of 5q spinal muscular atrophy (SMA) across the United Kingdom.

England, Wales and Northern Ireland

Following the publication of NICE's Multiple Technology Appraisal (MTA) guidance on 4 June 2026, the higher-dose regimen of nusinersen (50/28 mg) is now routinely commissioned through the NHS in England, Wales and Northern Ireland for the treatment of 5q SMA. The NICE guidance recommends that nusinersen can be used as an option for symptomatic and pre-symptomatic individuals with 5q SMA, provided it is not used in combination with risdiplam or after successful treatment with onasemnogene abeparvovec. Individuals seeking further information should discuss their care with their healthcare team.

Scotland

In Scotland, the Scottish Medicines Consortium (SMC) is currently undertaking a rapid review of the higher-dose regimen of nusinersen (50/28 mg) for the treatment of 5q SMA. A decision on its reimbursement within NHS Scotland is expected later in 2026.

Yours sincerely,

Nisha Tailor
External Affairs Lead, Biogen